These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9063906)

  • 41. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
    Young BK; Camicioli R; Ganzini L
    Drugs Aging; 1997 May; 10(5):367-83. PubMed ID: 9143857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.
    Mohr E; Mendis T; Hildebrand K; De Deyn PP
    Mov Disord; 2000 Nov; 15(6):1230-7. PubMed ID: 11104211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of clozapine in Brazilian patients with Parkinson's disease.
    Gomide L; Kummer A; Cardoso F; Teixeira AL
    Arq Neuropsiquiatr; 2008 Sep; 66(3B):611-4. PubMed ID: 18949249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of quetiapine in elderly patients.
    Tariot PN; Ismail MS
    J Clin Psychiatry; 2002; 63 Suppl 13():21-6. PubMed ID: 12562143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clozapine for the treatment of psychosis in Parkinson's disease: a review.
    Auzou P; Ozsancak C; Hannequin D; Moore N; Augustin P
    Acta Neurol Scand; 1996 Nov; 94(5):329-36. PubMed ID: 8947285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
    Tagai K; Nagata T; Shinagawa S; Tsuno N; Ozone M; Nakayama K
    Psychogeriatrics; 2013 Jun; 13(2):103-7. PubMed ID: 23909968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mirtazapine-induced worsening of restless legs syndrome (RLS) and ropinirole-induced psychosis: challenges in management of depression in RLS.
    Chopra A; Pendergrass DS; Bostwick JM
    Psychosomatics; 2011; 52(1):92-4. PubMed ID: 21300203
    [No Abstract]   [Full Text] [Related]  

  • 48. Dopamine dysregulation syndrome with psychosis in 24-hour intestinal levodopa infusion for Parkinson's disease.
    Ricciardi L; Espay KJ; Krikorian R; Fasano A; Espay AJ
    Parkinsonism Relat Disord; 2016 Jul; 28():152-4. PubMed ID: 27086263
    [No Abstract]   [Full Text] [Related]  

  • 49. [Parkinson's disease: current standards in diagnostics and therapy].
    Timmermann L; Eggers C; Salimi Dafsari H; Pauls KA; Barbe MT
    Fortschr Neurol Psychiatr; 2012 Oct; 80(10):560-9. PubMed ID: 23033202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What we have learned about sleep disorders and psychosis after nearly two centuries of Parkinson's disease. Summary and conclusions.
    Fernandez HH
    CNS Spectr; 2008 Mar; 13(3 Suppl 4):34-5. PubMed ID: 18323765
    [No Abstract]   [Full Text] [Related]  

  • 51. Neuroleptic malignant syndrome in cycloserine-induced psychosis.
    Sawant NS; Kate NS; Bhatankar SS; Kulkarni PS
    Indian J Pharmacol; 2015; 47(3):328-9. PubMed ID: 26069374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Iatrogenesis imperfecta.
    Friedman JH
    Med Health R I; 2002 Jul; 85(7):198. PubMed ID: 12182087
    [No Abstract]   [Full Text] [Related]  

  • 53. [Psychological changes in Parkinson disease].
    Danielczyk W
    Wien Med Wochenschr; 1986 Aug; 136(15-16):396-9. PubMed ID: 3788191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
    Juncos JL; Roberts VJ; Evatt ML; Jewart RD; Wood CD; Potter LS; Jou HC; Yeung PP
    Mov Disord; 2004 Jan; 19(1):29-35. PubMed ID: 14743357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopaminergic psychosis in advanced Parkinson's disease.
    Fischer P; Danielczyk W; Simanyi M; Streifler MB
    Adv Neurol; 1990; 53():391-7. PubMed ID: 2122647
    [No Abstract]   [Full Text] [Related]  

  • 56. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.
    Friedman JH; Factor SA
    Mov Disord; 2000 Mar; 15(2):201-11. PubMed ID: 10752567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
    Schindehütte J; Trenkwalder C
    Clin Neurol Neurosurg; 2007 Feb; 109(2):188-91. PubMed ID: 16949733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of later phases of Parkinson disease].
    Tison F
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F85-8. PubMed ID: 18680823
    [No Abstract]   [Full Text] [Related]  

  • 59. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis.
    Klein C; Prokhorov T; Miniovich A; Dobronevsky E; Rabey JM
    Clin Neuropharmacol; 2006; 29(4):215-9. PubMed ID: 16855423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A controlled study of the efficacy and safety of mianserin and amitriptyline in depressive inpatients.
    Möller HJ; Kasper S; Müller H; Kissling W; Fuger J; Ruhrmann S
    Pharmacopsychiatry; 1995 Nov; 28(6):249-52. PubMed ID: 8773291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.